首页> 外文期刊>Academic radiology >Multiparametric magnetic resonance imaging, spectroscopy and multinuclear ((2)(3)Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer.
【24h】

Multiparametric magnetic resonance imaging, spectroscopy and multinuclear ((2)(3)Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer.

机译:多参数磁共振成像,光谱学和多核((2)(3)Na)成像监测局部晚期乳腺癌的术前化疗。

获取原文
获取原文并翻译 | 示例
           

摘要

RATIONALE AND OBJECTIVES: The aim of this prospective study was to investigate using multiparametric and multinuclear magnetic resonance imaging during preoperative systemic therapy for locally advanced breast cancer. MATERIALS AND METHODS: Women with operable stage 2 or 3 breast cancer who received preoperative systemic therapy were studied using dynamic contrast-enhanced magnetic resonance imaging, magnetic resonance spectroscopy, and (2)(3)Na magnetic resonance. Quantitative metrics of choline peak signal-to-noise ratio, total tissue sodium concentration, tumor volumes, and Response Evaluation Criteria in Solid Tumors were determined and compared to final pathologic results using receiver-operating characteristic analysis. Hormonal markers were investigated. Statistical significance was set at P < .05. RESULTS: Eighteen eligible women were studied. Fifteen responded to therapy, four (22%) with pathologic complete response and 11 (61%) with pathologic partial response. Three patients (17%) had no response. Among estrogen receptor-positive, HER2-positive, and triple-negative phenotypes, observed frequencies of pathologic complete response, pathologic partial response, and no response were 2, 5, and 0; 1, 4, and 0; and 1, 1, and 3, respectively. Responders (pathologic complete response and pathologic partial response) had the largest reductions in choline signal-to-noise ratio (35%, from 7.2 +/- 2.3 to 4.6 +/- 2; P < .01) compared to nonresponders (11%, from 8.4 +/- 2.7 to 7.5 +/- 3.6; P = .13) after the first cycle. Total tissue sodium concentration significantly decreased in responders (27%, from 66 +/- 18 to 48.4 +/- 8 mmol/L; P = .01), while there was little change in nonresponders (51.7 +/- 7.6 to 56.5 +/- 1.6 mmol/L; P = .50). Lesion volume decreased in responders (40%, from 78 +/- 78 to 46 +/- 51 mm(3); P = .01) and nonresponders (21%, from 100 +/- 104 to 79.2 +/- 87 mm(3); P = .23) after the first cycle. The largest reduction in Response Evaluation Criteria in Solid Tumors occurred after the first treatment in responders (18%, from 24.5 +/- 20 to 20.2 +/- 18 mm; P = .01), with a slight decrease in tumor diameter noted in nonresponders (17%, from 23 +/- 19 to 19.2 +/- 19.1 mm; P = .80). CONCLUSIONS: Multiparametric and multinuclear imaging parameters were significantly reduced after the first cycle of preoperative systemic therapy in responders, specifically, choline signal-to-noise ratio and sodium. These new surrogate radiologic biomarkers maybe able to predict and provide a platform for potential adaptive therapy in patients.
机译:理由和目的:这项前瞻性研究的目的是研究在局部晚期乳腺癌的术前全身治疗期间使用多参数和多核磁共振成像技术。材料与方法:使用动态对比增强磁共振成像,磁共振波谱和(2)(3)Na磁共振对接受术前系统治疗的可手术的2或3期乳腺癌妇女进行研究。确定了胆碱峰值信噪比,总组织钠浓度,肿瘤体积和实体瘤反应评估标准的定量指标,并使用接受者操作特征分析与最终病理结果进行了比较。研究了激素标记。统计显着性设定为P <.05。结果:18名合格的妇女进行了研究。 15例对治疗有反应,4例(22%)有病理完全缓解,11例(61%)有病理部分缓解。三名患者(17%)无反应。在雌激素受体阳性,HER2阳性和三阴性表型中,观察到的病理完全应答,病理部分应答和无应答的频率分别为2、5和0; 1、4和0;和1、1、3。与无反应者(11%)相比,反应者(病理完全反应和病理部分反应)的胆碱信噪比降低幅度最大(35%,从7.2 +/- 2.3降低至4.6 +/- 2; P <.01) (从8.4 +/- 2.7到7.5 +/- 3.6; P = .13)。总组织钠浓度显着降低(27%,从66 +/- 18降至48.4 +/- 8 mmol / L; P = 0.01),而无应答者变化很小(51.7 +/- 7.6至56.5 + /-1.6 mmol / L; P = 0.50)。响应者的病变体积减少(40%,从78 +/- 78毫米降至46 +/- 51毫米(3); P = 0.01)和无反应者(21%,从100 +/- 104毫米降至79.2 +/- 87毫米) (3); P = 0.23)。实体瘤反应评估标准的最大减少发生在反应者首次治疗后(18%,从24.5 +/- 20毫米降低至20.2 +/- 18毫米; P = 0.01),肿瘤直径略有下降。无反应者(17%,从23 +/- 19到19.2 +/- 19.1毫米; P = .80)。结论:在响应者术前系统治疗的第一个周期后,多参数和多核显像参数显着降低,特别是胆碱信噪比和钠。这些新的替代放射生物标记物可能能够预测患者并为潜在的适应性治疗提供平台。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号